Cargando…

Response to: Amantadine, COVID-19 and Parkinsonism

Detalles Bibliográficos
Autor principal:	Aranda-Abreu, Gonzalo Emiliano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IMSS. Published by Elsevier Inc. 2020
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369578/ https://www.ncbi.nlm.nih.gov/pubmed/32723524 http://dx.doi.org/10.1016/j.arcmed.2020.07.002

Ejemplares similares

Amantadine, COVID-19 and Parkinsonism
por: Wiwanitkit, Viroj
Publicado: (2020)

Amantadine Treatment for People with COVID-19
por: Araújo, Ramiro, et al.
Publicado: (2020)

Amantadine as a drug to mitigate the effects of COVID-19
por: Aranda Abreu, Gonzalo Emiliano, et al.
Publicado: (2020)

Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2
por: Cortés-Borra, Albert, et al.
Publicado: (2021)

Investigation of the Long-Term Effects of Amantadine Use in Parkinson’s Disease
por: Park, Sangmin, et al.
Publicado: (2023)

Observational study of people infected with SARS-Cov-2, treated with amantadine
por: Aranda-Abreu, Gonzalo Emiliano, et al.
Publicado: (2020)

Oseltamivir- and Amantadine-Resistant Influenza Virus A (H1N1)
por: Cheng, Peter K.C., et al.
Publicado: (2010)

Paraneoplastic Chorea Managed with Intravenous Amantadine
por: Doher, Nicholas, et al.
Publicado: (2019)

Amantadine for the intractable hiccup when weaning a patient with a brainstem lesion-a case study
por: Sangeetha, RP, et al.
Publicado: (2023)

Could amantadine interfere with COVID-19 vaccines based on the LNP-mRNA platform?
por: Fedorowski, Jaroslaw J.
Publicado: (2021)

Amantadine-Induced Patulous Eustachian Tubes in Parkinson's Disease
por: Boyd, J. T., et al.
Publicado: (2013)

A possible antiviral effect of amantadine in an AH1N1 influenza-infected patient – a case report
por: Palaczyński, Piotr, et al.
Publicado: (2020)

Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial
por: Sawada, Hideyuki, et al.
Publicado: (2010)

An updated meta-analysis of amantadine for treating dyskinesia in Parkinson's disease
por: Kong, Min, et al.
Publicado: (2017)

Amantadine‐Induced Craniofacial Myoclonus: Distinctive Iatrogenic Dysarthria in Parkinson's Disease
por: Lin, Iris, et al.
Publicado: (2023)

Morbidity and severity of COVID-19 in patients with Parkinson's disease treated with amantadine - A multicenter, retrospective, observational study
por: Przytuła, Filip, et al.
Publicado: (2023)

AMANTADINE FOR POST-EXPOSURE PROPHYLAXIS IN COVID-19 IN WESTERN HONDURAS
por: MONTALVAN, ELEAZAR, et al.
Publicado: (2021)

Amantadine-Induced Cardiac Arrest in a Patient With COVID-19
por: Bakhati, Bibek, et al.
Publicado: (2022)

COVID-19: Implications for Sudden Death in Parkinson’s Disease
por: Fiorini, Ana Claudia, et al.
Publicado: (2021)

Molecular docking investigation of the amantadine binding to the enzymes upregulated or downregulated in Parkinson’s disease
por: Ionescu, Mihaela Ileana
Publicado: (2020)

Impact of Oral Fast Release Amantadine on Movement Performance in Patients with Parkinson’s Disease
por: Muhlack, Siegfried, et al.
Publicado: (2010)

Neuroprotective effect of Spirulina fusiform and amantadine in the 6-OHDA induced Parkinsonism in rats
por: Chattopadhyaya, I, et al.
Publicado: (2015)

Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study)
por: Pahwa, Rajesh, et al.
Publicado: (2015)

Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease
por: Sharma, Vibhash D, et al.
Publicado: (2018)

Parkinson’s disease following COVID-19: causal link or chance occurrence?
por: Li, Wei-Shan, et al.
Publicado: (2020)

Challenges in treating people with Parkinson’s disease during the COVID-19 pandemic
por: da Silva Rocha Paz, Thiago, et al.
Publicado: (2020)

An educational case series of Parkinson's disease during the COVID-19 pandemic
por: Lo Monaco, M.R., et al.
Publicado: (2021)

Care of Parkinson's disease (PD) patients in times of covid-19 pandemic
por: Chattopadhyay, Sidhartha
Publicado: (2021)

COVID-19 Associated Acute Necrotizing Encephalopathy Presenting as Parkinsonism and Myorhythmia
por: Ong, Tien Lee, et al.
Publicado: (2022)

Effect of COVID-19 Related Lockdown on Nonmotor Symptoms of Parkinson's Disease
por: Banerjee, Sourav, et al.
Publicado: (2022)

Erratum to: Neuroprotective effect of Spirulina fusiform and amantadine in the 6-OHDA induced Parkinsonism in rats
por: Chattopadhyaya, I., et al.
Publicado: (2015)

Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson’s Disease: An Open-Label, Pragmatic Trial
por: Kim, Aryun, et al.
Publicado: (2018)

Letter to the editor: risk comorbidities of COVID-19 in Parkinson’s disease patients in Germany
por: Richter, Daniel, et al.
Publicado: (2020)

Resilience and Trauma among Patients with Parkinson’s Disease during the COVID-19 Pandemic
por: Erro, Roberto, et al.
Publicado: (2022)

Novel Technologies Impact on Parkinson's & Alzheimer's Patient During the COVID-19 Pandemic
por: Chitsaz, Ahmad, et al.
Publicado: (2022)

Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment
por: Smieszek, Sandra P., et al.
Publicado: (2020)

Anti-Inflammatory Effects of Amantadine and Memantine: Possible Therapeutics for the Treatment of Covid-19?
por: Jiménez-Jiménez, Félix Javier, et al.
Publicado: (2020)

Amantadine Effect on Perceptions of Irritability after Traumatic Brain Injury: Results of the Amantadine Irritability Multisite Study
por: Hammond, Flora M., et al.
Publicado: (2015)

Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102
por: Isaacson, Stuart H., et al.
Publicado: (2018)

Effect of Repeated Intravenous Amantadine Infusions in Patients with Parkinson's Disease: An Open‐Label Pilot Study
por: Khlebtovsky, Alexander, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_uc0dv3krpscq2es1fjg21g4iks